Are Peptides Legal Again in 2026? Here is what RFK Jr. Just Announced
- Gary M. Rudashevsky, NP
- Mar 20
- 11 min read
The direction is changing, but the change is not yet complete.
Online sellers are already using RFK's statements to market products that remain legally unregulated. The announcement on Joe Rogan is creating more demand before any actual quality oversight is in place.
Key takeaways
RFK Jr. announced on Joe Rogan's show plans to restore legal compounding access for approximately 14 peptides
No formal FDA policy change has been issued yet (as of March 2026)
Sermorelin and NAD+ are already legal and available right now
Online "research" sources remain risky, no matter what policy changes come
The full list of 19 peptides placed on Category 2 in 2023 is broken down below
Licensed provider supervision matters more than ever during this transition
What is a peptide, and why should you care?
Peptides are short chains of amino acids. Amino acids are the building blocks of protein. When amino acids link up in short strings, they become peptides. When peptides link up into longer chains, they become proteins.
Your body already makes peptides every day. Insulin is a peptide. So are the hormones that control growth, reproduction, and tissue repair. The FDA has approved more than 100 peptide-based drugs over the decades, including GLP-1 medications like semaglutide, which millions of people now take for weight loss.
The controversy in the news right now is not about those approved medications. It is about a different group of compounds — things like BPC-157, CJC-1295, and Thymosin Alpha-1 — that compounding pharmacies used to prepare legally for patients under a doctor's supervision. In late 2023, the FDA moved 19 of these peptides to a restricted list. That move cut off access for patients who had been using them and created the gray market that now dominates online searches.
RFK Jr. wants to reverse that decision. Here is what we know, what is still unclear, and what it means for patients in the Twin Cities.
What happened in 2023?
On September 29, 2023, the FDA updated its list of bulk drug substances used in compounding pharmacies. The agency placed 19 peptides into "Category 2" of the FDA's 503A Bulk Drug Substances list. Category 2 means a compounding pharmacy cannot legally prepare that compound for a patient, even with a valid prescription from a licensed doctor.
The FDA said these peptides raised "significant safety concerns." The compounding pharmacy community, including the Alliance for Pharmacy Compounding (APC), pushed back immediately. They pointed out that the FDA had not released specific safety data to back up its claims. The APC sent a formal letter to FDA Director Gail Bormel in October 2023, requesting transparency into the process used to make these decisions.
Several compounding pharmacies filed a lawsuit arguing the FDA had skipped legally required steps. Those legal challenges forced the FDA to schedule public advisory committee meetings before taking further action.
The result: an entire category of treatments that doctors had been prescribing legally for years became inaccessible through legitimate channels overnight. Patients did not stop wanting them. They just started finding them from gray-market online vendors with no quality controls, no doctor involved, and no guarantee of what was actually in the vials.
The 19 peptides that were placed in Category 2
Here is the full list of compounds the FDA restricted from compounding in September 2023, with a note on what each one is and why patients were using it.
1. BPC-157 Short for Body Protection Compound 157. Found naturally in human stomach acid. Used for tissue repair, tendon healing, and gut health. Has more than 30 years of animal research and nearly 200 published studies behind it, but very limited human clinical trial data. Banned by the World Anti-Doping Agency (WADA). Currently on Category 2 with no clear path to reclassification.
2. CJC-1295 A growth hormone-releasing hormone (GHRH) analog. Stimulates the pituitary gland to release more growth hormone. Used for body composition, recovery, and anti-aging. One of the five peptides was removed from Category 2 in September 2024 and is currently undergoing PCAC review.
3. Ipamorelin Acetate: A growth hormone secretagogue. Triggers a clean pulse of growth hormone without raising cortisol or prolactin. Often paired with CJC-1295. Also removed from Category 2 in September 2024 and under PCAC review.
4. Thymosin Alpha-1 (Ta1) A peptide that naturally occurs in the human thymus gland. Has immune-modulating properties. Approved for use in more than 30 countries for treating hepatitis B, hepatitis C, and cancer-related immune support. Among the five removed from Category 2 in September 2024 and now under PCAC review.
5. AOD-9604 A fragment of human growth hormone studied for its fat-burning properties, with no androgenic side effects. One of the five peptides was removed from Category 2 in September 2024 and referred to PCAC.
6. Selank Acetate (TP-7) A synthetic analog of a naturally occurring immune peptide. Used in Russian medical research for anxiety reduction and cognitive support. Also, among the five referred to PCAC in September 2024.
7. Kisspeptin-10: A reproductive hormone that signals the brain to activate the sex hormone axis. Two randomized controlled trials published in JAMA Network Open by Imperial College London (2022 and 2023) found that kisspeptin significantly changed brain activity in key sexual processing regions in both women and men with low libido, with no reported adverse effects in either study. Under PCAC review since October 2024.
8. Ibutamoren Mesylate (MK-677) A non-peptide growth hormone secretagogue that is typically grouped with peptides in this conversation. Taken orally. Under PCAC review since October 2024.
9. Thymosin Beta-4, Fragment (TB-500) A synthetic fragment of the naturally occurring protein Thymosin Beta-4. Used for tissue repair, injury recovery, and anti-inflammatory effects. Remains on Category 2 with no current PCAC referral.
10. Epitalon (Epithalon) A tetrapeptide studied for telomere extension and anti-aging properties. Most research comes from Russian scientists and has not been well replicated in Western clinical settings. On Category 2 with no current PCAC pathway.
11. GHK-Cu (injectable) Copper peptide studied for anti-aging, wound healing, and collagen stimulation. Non-injectable forms remain available. The injectable route is what was moved to Category 2.
12. Melanotan II: A synthetic peptide that stimulates melanin production (tanning) and was also studied for sexual arousal effects. Has the most controversial safety profile on this list due to misuse patterns and skin cancer concerns.
13. KPV A tripeptide fragment studied for anti-inflammatory and gut health properties. Limited human clinical data.
14. MOTs-C A peptide derived from mitochondrial DNA. Research focuses on metabolic function, insulin sensitivity, and cellular energy production. Primarily animal and lab-based data.
15. Cathelicidin LL-37 is an antimicrobial peptide found naturally in human immune cells. Studied for wound healing and infection resistance. Limited clinical data outside dermatology research.
16. Dihexa Acetate: A nootropic peptide studied for cognitive enhancement and neuroprotection. Very limited human data. Primarily studied in rodent models of cognitive decline.
17. Emideltide (DSIP) Delta Sleep-Inducing Peptide. Studied for sleep regulation and stress response. Russian research background. Very limited English-language clinical evidence.
18. Semax (heptapeptide) A synthetic analog of ACTH studied for neuroprotection and cognitive support. Used medically in Russia. Limited Western clinical evidence.
19. Mechano Growth Factor, Pegylated (PEG-MGF) A variant of IGF-1 released in response to muscle damage. Studied for muscle repair and growth. Banned by WADA. Limited human safety data.
What changed in September 2024
On September 20, 2024, the FDA announced that five of the 19 peptides were being removed from Category 2: AOD-9604, CJC-1295, Ipamorelin Acetate, Thymosin Alpha-1, and Selank Acetate. They were removed because the original nominators withdrew their nominations, which allowed the FDA to refer them to the Pharmacy Compounding Advisory Committee (PCAC) for formal review.
PCAC review is the first step toward a compound gaining Category 1 status — meaning compounding pharmacies could legally prepare it again under proper oversight.
The PCAC reviewed Ipamorelin, Ibutamoren, and Kisspeptin-10 at its October 29, 2024, meeting. AOD-9604, CJC-1295, and Thymosin Alpha-1 were reviewed on December 4, 2024.
Those reviews do not automatically restore access — they are the beginning of a formal evaluation process that still requires a notice-and-comment period before any final determination.
What did RFK Jr. actually say?
On a recent Joe Rogan podcast episode, RFK Jr. called the 2023 Category 2 reclassifications illegal. His argument was that the FDA is only allowed to restrict compounding based on safety concerns — not efficacy concerns — and that the 2023 action crossed that legal line.
He acknowledged directly: "We created the gray market."
He stated that he wants to move approximately 14 peptides from Category 2 back to Category 1, restoring legal access through licensed compounding pharmacies with proper quality oversight.
He indicated a formal FDA announcement could come within weeks of the recording.
As of March 2026, that formal policy change has not been issued.
The practical takeaway:
The direction is changing, but the change is not yet complete. Online sellers are already using RFK's statements to market products that remain legally unregulated. The announcement creates demand before any actual quality oversight is in place.
Why sourcing still matters more than ever
When compounding pharmacies legally prepare medications, they must follow USP 797 and USP 795 standards for sterile and non-sterile compounding, respectively.
Their active pharmaceutical ingredients must come from FDA-registered manufacturers with Certificates of Analysis confirming purity, potency, and sterility.
None of that applies to vials sold online as "research use only."
Independent lab testing across online peptide vendors has found that approximately 8% of all samples tested contained measurable endotoxins — bacterial fragments that can cause fever, chills, or septic shock at higher concentrations. Some samples contained none of the labeled compound.
In 2025, two women were hospitalized and placed on ventilators after receiving peptide injections at a longevity conference in Las Vegas.
These are documented outcomes from the gray market that exists precisely because the 2023 ban pushed patients away from legitimate channels. When licensed pharmacies can once again legally prepare these compounds, the quality difference becomes concrete and measurable — not theoretical.
What is available legally "for human consumption" right now in Edina?
Two peptides have always been legally compoundable and remain available today.
Sermorelin is a GHRH analog — it signals your pituitary to produce and release its own growth hormone rather than replacing it directly. Because it works upstream, your body's natural feedback systems stay active. The pituitary can only release as much growth hormone as it is naturally capable of producing, so sermorelin cannot push growth hormone to unsafe levels. The FDA previously approved sermorelin under the brand name Geref for growth hormone deficiency in children before the manufacturer discontinued it for commercial reasons in 2008, not for safety concerns.
NAD+ (nicotinamide adenine dinucleotide) is a molecule your cells use to produce energy and repair DNA. Levels decline with age. IV, IM, or Subcutaneous injection supplementation supports the energy systems that hormone optimization also targets. It is legally compoundable now with no regulatory uncertainty.
When CJC-1295, Ipamorelin, Kisspeptin-10, or other compounds become available through legitimate compounding channels after completing the PCAC process, we will evaluate the clinical evidence and offer them as part of comprehensive treatment plans.
We will not offer gray-market products before that happens.
What the research actually shows
The online peptide conversations tend toward two extremes that both miss the real picture:
The first is uncritical hype — treating every compound as a proven cure.
The second is blanket dismissal — the position that anything without a large randomized controlled trial has no clinical value.
Here is where the evidence actually stands by compound.
Kisspeptin has the strongest human evidence of any compound currently on Category 2. Two separate double-blind, placebo-controlled randomized trials from Imperial College London — published in JAMA Network Open in 2022 (women) and 2023 (men) — found that kisspeptin significantly changed brain activity in key sexual processing regions in people with hypoactive sexual desire disorder (HSDD). The 2023 trial in men found a physical arousal response up to 56% greater than placebo. Neither trial reported adverse effects. The limitation: both trials used single-dose infusions. Long-term dosing and safety data in humans do not yet exist.
CJC-1295 and Ipamorelin have meaningful human data showing restoration of growth hormone pulse patterns, with downstream effects on body composition and sleep quality. Because they work upstream of growth hormone, the body's own feedback systems remain active, and supraphysiologic levels cannot be produced.
BPC-157 has extensive animal research but almost no human-controlled trial data. The FDA's concerns about immunogenicity at certain injection routes and inconsistent pharmaceutical-grade characterization across suppliers are legitimate issues — not invented ones. BPC-157 is also banned by WADA. Any clinical use should be undertaken with an honest acknowledgment of what the evidence does and does not support.
Thymosin Alpha-1 has the longest human safety record on this list. It has been approved in more than 30 countries for decades. It's relatively quick movement through PCAC review reflects that history.
The pattern: real promise, incomplete human data. That is a reason for proper medical supervision — not for dismissal or for DIY supplementation.
The advantage of working with a licensed medical practice
The patients most at risk right now are not "hardcore biohackers" who understand the gray market. They are often people with no medical background who heard something promising on a podcast or on TikTok and want to try something that might help with their shoulder pain, energy, or libido.
For those patients, where a compound comes from and who is supervising its use is more important than which compound it is.
At Medical Specialists in Edina, we have followed peptide research for over a decade. We offer in-house lab testing that establishes your hormone levels and key biomarkers before any treatment decision is made.
When these compounds become available through legitimate compounding pharmacy channels, we will be positioned to incorporate them into treatment plans that account for your full hormonal picture — not just what is trending online.
Call (952) 225-5400 or fill out the form below to schedule a consultation.
Frequently asked questions
Q: Are peptides legal right now?
A: It depends on the peptide. Sermorelin and NAD+ are legal to compound and available now. The 19 peptides placed on Category 2 in 2023 cannot currently be legally compounded. Five of those (CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, and Selank) are moving through the FDA's formal review process. RFK Jr. has stated a goal of returning approximately 14 to legal status, but no formal policy change has been issued as of March 2026.
Q: Can I buy peptides online?
A: Many websites sell peptides labeled "for research purposes only." That label is a legal workaround. It does not mean the products are safe, pure, or accurately labeled. Independent testing has found endotoxin contamination in approximately 8% of samples tested across vendors, and some samples contained none of the labeled compound. Buying and self-administering these compounds without medical supervision carries real, documented risk.
Q: What peptides does Medical Specialists currently offer?
A: We offer sermorelin and NAD+, both of which are now legally compoundable. As CJC-1295, Ipamorelin, Kisspeptin-10, and other compounds complete the PCAC review process, we will evaluate the clinical evidence and offer them through licensed compounding pharmacies as appropriate. We do not offer gray-market products.
Q: What is the difference between sermorelin and human growth hormone?
A: Sermorelin signals your pituitary to produce its own growth hormone. It works upstream and preserves your body's natural feedback system. Exogenous human growth hormone replaces the hormone directly and suppresses your body's own production. Sermorelin cannot push growth hormone to unsafe levels because it is limited by your pituitary's natural capacity.
Q: How does this connect to TRT and BHRT?
A: Several peptides under review are directly relevant to patients on hormone therapy. Kisspeptin may address libido signaling that TRT does not fully restore. CJC-1295 and Ipamorelin support growth hormone and sleep quality, which affect body composition and hormonal health. NAD+ supports the cellular energy systems that hormone optimization also targets. For patients whose hormone therapy results feel incomplete, some of these peptides may address the gaps.
Q: How do I know if a peptide is right for me?
A: It starts with knowing where you actually are — hormone levels, metabolic markers, symptoms, and goals. Peptides work best as part of a comprehensive plan, not as a standalone answer. Start with a consultation and lab panel.
Sources
Restore Health Consulting. FDA Adds Several Peptides to Category 2 Bulks List. December 5, 2024. https://www.restorehealthconsulting.com/news/fda-adds-several-peptides-to-category-2-bulks-list-restricting-them-from-compounding
Lexology / Reed Smith. FDA Removes Certain Peptide Bulk Drug Substances from Category 2 of Interim 503A Bulks List. October 1, 2024. https://www.lexology.com/library/detail.aspx?g=2e55b76a-3173-4e04-beda-bf021202f18d
Frier Levitt. Regulatory Status of Peptide Compounding in 2025. April 3, 2025. https://www.frierlevitt.com/articles/regulatory-status-of-peptide-compounding-in-2025/
Safe Harbor Group. FDA's Overreach on Compounded Peptides. February 2026. https://www.safehg.com/fdas-overreach-on-compounded-peptides-legal-battles-and-how-clinics-can-push-back/
NCPA. FDA Releases Guidance for Compounding Pharmacies. January 13, 2025. https://ncpa.org/newsroom/qam/2025/01/13/fda-releases-guidance-compounding-pharmacies
Thurston L, et al. Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Network Open. 2022;5(10):e2236131. doi:10.1001/jamanetworkopen.2022.36131
Mills EG, et al. Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Network Open. 2023;6(2):e2254313. doi:10.1001/jamanetworkopen.2022.54313
USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. September 25, 2025. https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/
EVEXIAS Health Solutions. An Affront to Health Freedom: The FDA Recategorizes 17 Therapeutic Peptides. October 2025. https://www.evexias.com/an-affront-to-health-freedom-the-fda-recategorizes-17-therapeutic-peptides/
FDA 503A Bulk Drug Substances List (September 27, 2024). https://www.fda.gov/media/94155/download
Yoon Hang Kim MD. Legal Peptide Compounding Guide: 503A & 503B Regulatory Compliance. January 23, 2026. https://www.yoonhangkim.com/post/legal-peptide-compounding-guide503a-503b-regulatory-compliance
The Peptide List / Medium. The FDA Peptide Regulations Explained. February 2026. https://medium.com/@andrei_91292/the-fda-peptide-regulations-explained-whats-legal-what-s-not-and-what-s-coming-f94138238a2d
This article is for educational purposes only and does not constitute medical advice. The regulatory status of peptide therapies is actively evolving. Always consult a qualified healthcare provider before starting any new treatment.
Medical Specialists only offers legal peptide therapies compounded through legally compliant channels under licensed medical supervision.